

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,896,879 B2  
DATED : May 24, 2005  
INVENTOR(S) : Eyal Talor

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3, line 64 to Column 4, line 19,

Should read as follows:

-- In other specific applications, the serum-free and mitogen-free cytokine preparation or pharmaceutical composition has further different cytokines and other small biologically active molecules in Multikine® wherein the ratio of each of the small biologically active molecules to IL-2 is as follows: IL-3 to IL-2 in a ratio range of 0.38 - 0.68, preferably at 0.53 +/-0.15, IL-6 to IL-2 in a ratio range of 37.2 - 53.8, preferably at 46 +/-5.9, IL-8 to IL-2 in a ratio range of 261 - 561.5, preferably at 411 +/-10.6, IL-1 $\alpha$  to IL-2 in a ratio range of 0.56 - 0.94, preferably at 0.75 +/-0.19, IL-10 to IL-2 in a ratio range of 2.82 - 3.22, preferably at 3.0 +/-0.18, IL-16 to IL-2 in a ratio range of 1.16 - 2.84, preferably at 1.84 +/-0.68, G-CSF to IL-2 in a ratio range of 2.16 - 3.78, preferably at 2.97 +/-0.81, TNF- $\beta$  to IL-2 in a ratio range of 1.17 - 2.43, preferably at 1.8 +/-0.63, MIP-1 $\alpha$  to IL-2 in a ratio range of 15.7 - 37.16, preferably at 22.7 +/-7.0, MIP-1 $\beta$  to IL-2 in a ratio range of 17.1 - 28.5, preferably at 22.8 +/-5.7, a RANTES to IL-2 in a ratio range of 2.3 - 2.7, preferably at 2.5 +/-0.13, a EGF to IL-2 in a ratio range of 0.267 - 0.283, preferably at 0.275 +/-0.008, PGE<sub>2</sub> to IL-2 in a ratio range of 3.63 - 5.42, preferably at 4.5 +/-0.87 and TxB<sub>2</sub> to IL-2 in a ratio range of 23.47 - 25.13, preferably at 24.3 +/-0.83. --.

Column 6,

Lines 4-23 should read as follows:

-- The remainder of the different cytokines and other small biologically active molecules in Multikine® are also present within each preparation of the small biologically active molecules to IL-2 as follows: IL-3 to IL-2 in a ratio range of 0.38 - 0.68, preferably at 0.53 +/-0.15, IL-6 to IL-2 in a ratio range of 37.2 - 53.8, preferably at 46 +/-5.9, IL-8 to IL-2 in a ratio range of 261 - 561.5, preferably at 411 +/-10.6, IL-1 $\alpha$  to IL-2 in a ratio range of 0.56 - 0.94, preferably at 0.75 +/-0.19, IL-10 to IL-2 in a ratio range of 2.82 - 3.22, preferably at 3.0 +/-0.18, IL-16 to IL-2 in a ratio range of 1.16 - 2.84, preferably at 1.84 +/-0.68, G-CSF to IL-2 in a ratio range of 2.16 - 3.78, preferably at 2.97 +/-0.81, TNF- $\beta$  to IL-2 in a ratio range of 1.17 - 2.43, preferably at 1.8 +/-0.63, MIP-1 $\alpha$  to IL-2 in a ratio range of 15.7 - 37.16, preferably at 22.7 +/-7.0, MIP-1 $\beta$  to IL-2 in a ratio range of 17.1 - 28.5, preferably at 22.8 +/-5.7, a RANTES to IL-2 in a ratio range of 2.3 - 2.7, preferably at 2.5 +/-0.13, a EGF to IL-2 in a ratio range of 0.267 - 0.283, preferably at 0.275 +/-0.008, PGE<sub>2</sub> to IL-2 in a ratio range of 3.63 - 5.42,

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,896,879 B2  
DATED : May 24, 2005  
INVENTOR(S) : Eyal Talor


Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 6 (cont'd),  
preferably at 4.5 +/-0.87 and TxB<sub>2</sub> to IL-2 in a ratio range of 23.47 - 25.13, preferably at 24.3 +/-0.83. --.

Signed and Sealed this

Twenty-seventh Day of September, 2005



JON W. DUDAS  
*Director of the United States Patent and Trademark Office*